Germ-line and Somatic PTPN11 Mutations in Human Disease
Overview
Authors
Affiliations
Reversible protein tyrosyl phosphorylation of cell surface receptors and downstream intracellular transducers is a major regulatory mechanism used to modulate cellular responses to extracellular stimuli, and its deregulation frequently drives aberrant cell proliferation, survival and/or differentiation. SHP-2 is a cytoplasmic Src-homology 2 domain-containing protein tyrosine phosphatase that plays an important role in intracellular signaling and is required during development and hematopoiesis. Germ-line missense mutations in PTPN11, the gene coding SHP-2, have been discovered as a major molecular event underlying Noonan syndrome, an autosomal dominant trait characterized by short stature, dysmorphic facies, and congenital heart defects, as well as in other closely related developmental disorders. More recently, a distinct class of missense mutations in the same gene has been identified to occur as a somatic event contributing to myeloid and lymphoid malignancies. This review focuses on the role of SHP-2 in signal transduction, development and hematopoiesis, as well as on the consequences of SHP-2 gain-of-function.
Complex Roles of /SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy.
Scheiter A, Lu L, Gao L, Feng G Annu Rev Cancer Biol. 2025; 8(1):15-33.
PMID: 39959686 PMC: 11824402. DOI: 10.1146/annurev-cancerbio-062722-013740.
Singh P, Kumar V, Lee K, Hong J Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065785 PMC: 11280062. DOI: 10.3390/ph17070935.
Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice.
Fuentes-Mateos R, Garcia-Navas R, Fernandez-Infante C, Hernandez-Cano L, Calzada-Nieto N, Olarte-San Juan A Cell Commun Signal. 2024; 22(1):332.
PMID: 38886790 PMC: 11184836. DOI: 10.1186/s12964-024-01717-4.
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation.
Miao J, Zhang Z ChemMedChem. 2024; 19(7):e202300669.
PMID: 38233347 PMC: 11021144. DOI: 10.1002/cmdc.202300669.
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition.
Lai X, Lui S, Lam H, Adachi Y, Sim W, Vasilevski N NPJ Precis Oncol. 2023; 7(1):136.
PMID: 38102334 PMC: 10724235. DOI: 10.1038/s41698-023-00486-6.